Medically reviewed on Jan 20, 2019
(e KAL lan tide)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Subcutaneous [preservative free]:
Kalbitor: 10 mg/mL (1 mL)
Brand Names: U.S.
- Kallikrein Inhibitor
Ecallantide is a recombinant protein which inhibits the conversion of high molecular weight kininogen to bradykinin by selectively and reversibly inhibiting plasma kallikrein. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.
Vd: 26.4 ± 7.8 L
Onset of Action
30 minutes to 4 hours (Epstein 2008)
Time to Peak
~2 to 3 hours
2 ± 0.5 hours
Use: Labeled Indications
Hereditary angioedema: Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years and older
Hypersensitivity to ecallantide or any component of the formulation
Hereditary angioedema (HAE) treatment: SubQ: 30 mg (as three 10 mg [1 mL] injections); if attack persists, may repeat an additional 30 mg within 24 hours
Refer to adult dosing.
Hereditary angioedema (HAE), treatment:
Children 8 to <12 years of age: Limited data available: SubQ: 30 mg (as three 10 mg [1 mL] injections); dosing based on data pooled from four clinical studies (n=29, ages 9 to 17 years including 25 who received at least one dose of ecallantide) (MacGinnitie, 2013) and a single case report in an 8-year old (Dy, 2013); efficacy was observed with no adverse events reported.
Children ≥12 years and Adolescents: SubQ: 30 mg (as three 10 mg [1 mL] injections); if attack persists, may repeat an additional 30 mg within 24 hours
SubQ: Administer as 3 (10 mg/mL each) injections subcutaneously into skin of abdomen, upper arm, or thigh (do not administer at site of attack). Recommended needle size is 27 gauge. Separate injections by 2 inches (5 cm). May inject all doses in same or different location; rotation of sites is not necessary. Monitor/observe for hypersensitivity. Should only be administered by a health care professional; not for self-administration.
Store at 2°C to 8°C (36°F to 46°F). Protect from light. May be stored for up to 14 days at <30°C (<86°F).
There are no known significant interactions.
Central nervous system: Headache (8% to 16%), fatigue (12%)
Gastrointestinal: Nausea (5% to 13%), diarrhea (4% to 11%)
Immunologic: Antibody development (IgE: 5% to 20%; neutralizing: 9%)
1% to 10%:
Dermatologic: Pruritus (5%), skin rash (3%), urticaria (2%)
Gastrointestinal: Vomiting (6%), upper abdominal pain (5%)
Hypersensitivity: Anaphylaxis (4%)
Local: Injection site reaction (3% to 7%; includes bruising, erythema, irritation, pain, pruritus, urticaria)
Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (3% to 6%)
Miscellaneous: Fever (4% to 5%)
<1%, postmarketing, and/or case reports: Hypersensitivity reaction (chest discomfort, flushing, pharyngeal edema, rhinorrhea, sneezing, nasal congestion, throat irritation, wheezing, hypotension)
Concerns related to adverse effects:
• Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions, including anaphylaxis have been reported; administer only by healthcare provider in presence of appropriate medical support to manage anaphylaxis and hereditary angioedema. Do not administer to patients with known hypersensitivity to ecallantide. Reactions usually occur within 1 hour and may include chest discomfort, flushing, hypotension, nasal congestion, pharyngeal edema, pruritus, rash, rhinorrhea, sneezing, throat irritation, urticaria, and wheezing. Signs/symptoms of hypersensitivity reactions may be similar to those associated with hereditary angioedema attacks, therefore, consideration should be given to treatment methods; monitor patients closely.
• Immunogenicity: Some patients may develop antibodies to ecallantide during therapy; seroconversion may increase the risk of hypersensitivity reaction.
Monitor for hypersensitivity reaction
Pregnancy Risk Factor
Adverse effects were observed in animal reproduction studies. If treatment for hereditary angioedema (HAE) is needed during pregnancy, other agents are recommended (WAO/EEACI [Maurer 2018]).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience headache, loss of strength and energy, nausea, vomiting, diarrhea, or abdominal pain. Have patient report immediately to prescriber severe injection site irritation, difficulty swallowing, shortness of breath, dizziness, passing out, tachycardia, abnormal heartbeat, anxiety, flushing, rhinorrhea, nose irritation, throat irritation, or sneezing (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about ecallantide
- Ecallantide Side Effects
- During Pregnancy
- Dosage Information
- Compare Alternatives
- En Español
- 1 Review
- Drug class: miscellaneous coagulation modifiers
Other brands: Kalbitor